This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Bullous Pemphigoid수포성 유사천포창 (수포성유사천포창)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: L12.0 | Special Copayment Reduction: V211 (rare disease)
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood very high — Bullous pemphigoid typically first occurs in the elderly aged 65 or older, and onset before adulthood is extremely rare. The typical pattern of prodromal pruritus lasting several months before blisters appear makes onset in adulthood, especially old age, an essential characteristic.
1. History1953: first distinguished by Lever → identification of the BP180/BP230 antigens → reports of dupilumab-associated onset.
2. CausesIgG·IgE autoantibodies against BP180 (COL17A1) and BP230 (BPAG1). Risk factors: old age, neurological disease, certain drugs (such as DPP-4 inhibitors).
3. GeneticsAssociated with HLA-DQB1*03:01. Pathogenic variants of the COL17A1 and DST genes themselves are not the cause. A complex genetic disease.
4. General epidemiologyPredominantly affects the elderly aged 65 or older. Annual incidence 2~21 per million. Incidence trending upward with population aging.
5. PathophysiologyAnti-BP180 IgG → damage to basement membrane hemidesmosomes → activation of eosinophils·mast cells → subepidermal blisters.
6. SymptomsProdromal pruritic erythematous phase (weeks~months) → flaccid or tense blisters, severe pruritus. Oral involvement about 10~20%.
7. SignsTense blisters, urticarial plaques, pruritic erythema. Nikolsky negative. Peripheral blood eosinophilia, anti-BP180/BP230 ELISA positive.
8. ScreeningAnti-BP180 NC16A ELISA (sensitivity 80~90%), anti-BP230 ELISA. Performed in elderly patients with pruritus·blisters.
9. DiagnosisHistopathology (subepidermal blister, eosinophil infiltration), DIF (linear IgG·C3 deposition at the basement membrane), ELISA.
10. TreatmentPotent topical steroids (first-line), systemic steroids, doxycycline+niacinamide, methotrexate, omalizumab, dupilumab.
11. Prognosis1-year mortality about 20~40% due to age-related comorbidities. Relapse common. Poor prognosis with neurological comorbidity.
12. PreventionMaintenance treatment, prevention of secondary infection, minimizing fall risk, monitoring of steroid adverse effects.
13. ReferencesMurrell DF et al. J Am Acad Dermatol 2012 and 9 others.

1. History

Bullous pemphigoid (BP) was first described in 1953 by the American dermatologist Walter F. Lever as a distinct blistering disease clinically·histologically different from pemphigus. Lever proposed as the main distinguishing criteria that the blisters form subepidermally rather than intraepidermally (as in pemphigus), and that the disease is characterized by tense blisters in elderly patients. Subsequently, in 1963, Ernst Beutner and Robert Jordon discovered by indirect immunofluorescence autoantibodies in the serum of BP patients that bind to the basement membrane zone (BMZ), establishing the autoimmune mechanism.

In the 1980s, BP autoantigens began to be partially purified, and two main target antigens were identified. BP180 (BPAG2, type XVII collagen, COL17A1) was characterized at the molecular level in 1990, and BP230 (BPAG1) in 1988. BP180 was shown to be a transmembrane collagen making up hemidesmosomes, with the NC16A region of its extracellular domain being the main target epitope of autoantibodies. This discovery led to the development of the anti-BP180 NC16A ELISA, now used as the standard serological test for BP diagnosis.

In the history of treatment, the introduction of systemic corticosteroids in the 1950s~60s was the first milestone, followed by the development of azathioprine, methotrexate, and minocycline+niacinamide combination. In 2002, a French multicenter randomized controlled trial (Joly et al.) demonstrated that potent topical corticosteroids (clobetasol propionate 40 g/day) were as effective as or superior to systemic steroids in severe BP with fewer adverse effects, changing the treatment paradigm. Recently, BP associated with DPP-4 inhibitors (gliflozin-class diabetes drugs) and dupilumab has been reported, raising interest in drug-induced BP. Clinical trials of new biologics such as omalizumab, bezlotoxumab, and dupilumab are underway.

In Korea as well, BP incidence is increasing with the growth of the elderly population, and research on domestic epidemiology, clinical features, and treatment outcomes is accumulating, centered on the Korean Dermatological Association and related journals. Registration for Special Copayment Reduction V211 partly reduces the burden of treatment costs.

2. Causes

Bullous pemphigoid is an autoimmune blistering disease caused by autoantibodies against BP180 (COL17A1, type XVII collagen) and BP230 (BPAG1), components of the hemidesmosomes at the dermal-epidermal junction (DEJ). Both antigens are essential components of the hemidesmosomes that attach basal keratinocytes to the basement membrane.

BP180 is a transmembrane protein whose intracellular domain binds BP230 and plectin, and its extracellular NC16A domain is the main target of autoantibodies. When anti-BP180 IgG (especially IgG4) binds to NC16A, the structural integrity of the hemidesmosome is impaired, and complement activation and proteolytic enzymes derived from mast cells·eosinophils·neutrophils (MMP-9, elastase) degrade the basement membrane, resulting in epidermal-dermal separation. IgE autoantibodies are also detected in some patients, and an allergy-like mechanism via mast cells and eosinophils explains the severe pruritus and eosinophilia of BP.

Risk factors associated with the development of BP include old age (65 or older), neurological diseases (Alzheimer disease, Parkinson disease, stroke, multiple sclerosis, epilepsy), psychiatric disorders, drugs (DPP-4 inhibitors, furosemide, ampicillin, PUVA therapy, radiation therapy), and malignancies (in a minority). BP due to DPP-4 inhibitors (the gliptin class) is characterized by antibodies against the C-terminal domain of BP180 instead of anti-BP180 NC16A antibodies. There are also reports that dupilumab (IL-4/13 receptor blockade) induces or worsens BP, which may be related to relative enhancement of Th17 or Th1 immunity after Th2 suppression.

3. Genetics

BP is a complex genetic disease associated with specific HLA class II genotypes. The most consistently reported risk allele is HLA-DQB1*03:01, with a moderate association (odds ratio about 2~4) confirmed in several European cohorts. HLA-DR4, DR11, and DR15 are also reported in some populations. The strength of the HLA association is weaker than in pemphigus, and genetic predisposition alone can hardly explain the development of the disease.

Variants in the COL17A1 gene (10q25.1) are not the cause of BP. Heterozygous and homozygous loss-of-function mutations of COL17A1 cause junctional epidermolysis bullosa and some skin atrophy disorders, but these are unrelated to autoimmune mechanisms. Pathogenic variants in the DST gene (6p12.1, encoding BP230/BPAG1) are also not a cause of BP.

GWAS-level genomic studies of BP are still limited, but polymorphisms in IL-13, CTLA4, FcγRIII (CD16), and others have been reported as non-HLA risk genes in some studies. Genetic findings suggesting involvement of the IL-4/13 signaling pathway and IgE-mediated mechanisms provide a rationale for Th2-targeted therapies such as dupilumab. The clinical significance of genetic counseling is limited, and familial clustering is rare.

4. General epidemiology

Bullous pemphigoid is the most common autoimmune blistering disease in developed countries, with an annual incidence reported variously as 2~21 per million population depending on region and study method. France (about 21/million), Germany (about 13/million), and the UK (about 4~5/million) show relatively high incidence, reflecting differences in the proportion of the elderly population and diagnostic systems. In East Asia, incidence is lower than in the West but is trending upward with population aging.

Age of onset is concentrated mainly in the elderly aged 65 or older, with a mean age at diagnosis of about 75~80 years. Incidence increases sharply above age 80. It also occurs rarely in young adults and children. The sex distribution is slightly female-predominant or similar. A meta-analysis found a 5~10-fold increased risk of BP in people with neurological diseases, and since small amounts of anti-BP180 antibodies are sometimes detected in the blood of elderly people without BP, immunosenescence is presumed to increase the risk of disease. In aging societies, the socioeconomic burden of BP is gradually increasing.

5. Pathophysiology

The pathophysiology of BP begins with structural destruction of basal keratinocyte hemidesmosomes. When anti-BP180 NC16A IgG autoantibodies bind to the extracellular domain of BP180 in basal keratinocyte hemidesmosomes, complement activation (generation of C3b, C5a) occurs, and C5a chemoattracts mast cells and eosinophil precursors, causing them to migrate into local tissue. Activated mast cells secrete proteases, histamine, and interleukins (IL-4, IL-5, IL-13), and eosinophils secrete eosinophil cationic protein (ECP), major basic protein (MBP), MMP-9, and others, which degrade laminin-332, COL17A1, and COL7A1 of the basement membrane. As a result, a split develops at the epidermal-dermal junction and subepidermal blisters form.

Anti-BP180 IgE autoantibodies bind to FcεRI receptors on cutaneous mast cells and induce degranulation, causing severe pruritus and urticarial reactions through histamine and tryptase release. This is the mechanism of the intense pruritus and prodromal urticarial lesions characteristic of BP. At the T-cell level, BP180·BP230-specific CD4+ T helper cells secrete Th2-skewed cytokines (IL-4, IL-5, IL-13), promoting production of IgG4 and IgE autoantibodies by B cells. As a mechanism for the association between neurological disease and BP, there is a hypothesis that BP180-like proteins (such as neuropilin-1) are also expressed in neurons, so a neural autoimmune response may cross-trigger skin autoimmunity.

6. Symptoms

The clinical course of bullous pemphigoid is typically divided into a prodromal phase and a bullous phase. The prodromal phase lasts for weeks to months, with severe pruritus, urticarial erythematous plaques, eczematous lesions, and papules·nodules without obvious blisters. During this phase, it is often mistaken for urticaria, eczema, or drug reactions, delaying diagnosis.

The bullous phase is characterized by tense blisters arising on normal or erythematous skin. The blisters contain serous or hemorrhagic contents and have thick, firm walls, so unlike the flaccid blisters of pemphigus they remain intact for several days. They range in diameter from a few millimeters to several centimeters. The main sites are the inner thighs, groin, axillae, and flexural areas, but they may be distributed generally. Pruritus is very severe and greatly impairs quality of life, and sleep disturbance from nocturnal pruritus is common.

Oral mucosal involvement occurs in about 10~20%, is milder than in pemphigus, and blisters persist longer rather than erosions. Involvement of the esophageal, nasal, conjunctival, and anogenital mucosa is rare. Systemic symptoms (fever, weight loss) may be present in severe cases but are milder than in pemphigus. In elderly patients with extensive skin involvement, loss of the skin barrier, secondary infection, sepsis, and cardiovascular burden increase the risk of death.

7. Signs

The most characteristic physical sign of bullous pemphigoid is tense blisters. The blister walls are thick and firm and do not rupture easily even with finger pressure, which distinguishes them from the thin, flaccid blisters of pemphigus vulgaris. The Nikolsky sign is typically negative in BP, which is useful in clinical differentiation from pemphigus. Urticarial erythematous plaques are seen around the blisters, and scratch marks (scars) from severe pruritus may remain on the skin.

On skin examination, lesions at various stages coexist: urticarial erythematous plaques (prodromal phase), intact tense blisters, moist erosions after rupture, healing crusts, and pigmented scars. The inner thighs, flexural areas, and abdomen are the main sites, but lesions may be distributed throughout the limbs·trunk. Scalp involvement presents as erosive scalp dermatitis, and in pediatric BP, vulvar·groin involvement is prominent (childhood vulval BP). On oral mucosal examination, mucosal blisters·erosions are found in a minority.

The most characteristic laboratory finding is peripheral blood eosinophilia (about 50% of patients), and elevated serum IgE, positive anti-BP180 NC16A ELISA, and positive anti-BP230 ELISA (in some) are used for diagnosis. DIF shows linear IgG and C3 deposition along the basement membrane zone. Elevated inflammatory markers (CRP, ESR) and hypoalbuminemia (with extensive exudation) may be present.

8. Screening

Screening for bullous pemphigoid is mainly targeted at patients aged 65 or older presenting with unexplained pruritus, urticarial lesions, or a bullous eruption. In particular, anti-BP180 ELISA is considered for pruritus or urticarial lesions persisting for several weeks or more.

Anti-BP180 NC16A ELISA is the most useful screening test for BP, with a sensitivity of about 80~90% and a specificity of about 90~98%. Antibody titers are generally proportional to disease activity and are used to monitor treatment response and predict relapse. Anti-BP230 ELISA has lower sensitivity (about 60%) but is used as a complement in suspected patients negative for BP180 alone. Combining the two tests can raise diagnostic sensitivity to about 95%.

Indirect immunofluorescence (IIF): Using normal human skin or NaCl-split skin (salt-split skin) as substrate, linear IgG fluorescence at the basement membrane zone is confirmed. On NaCl-split skin (epidermal side in BP, dermal side in epidermolysis bullosa acquisita), the location of fluorescence can partly distinguish BP from epidermolysis bullosa acquisita. IIF is used as a complement when ELISA is negative but clinical suspicion is high.

When the screening test is positive or clinical suspicion is high, biopsy and DIF are performed for confirmation. When BP symptoms develop in a patient taking a DPP-4 inhibitor, the role of the drug is considered and discontinuation is reviewed where possible.

9. Diagnosis

The diagnosis of BP is made by integrating clinical findings, histopathology, DIF, and serum autoantibody testing. The German BP diagnostic criteria (modified Venning & Wojnarowska criteria) and EDF guidelines are referenced. The standard is to perform at least one of histopathology and DIF, plus serum autoantibody testing.

Histopathology: A punch biopsy is taken from the edge of a fresh blister. On H&E staining, a subepidermal blister with eosinophil and neutrophil infiltration in the dermal papillae is the typical finding. In prodromal lesions, only eosinophilic spongiosis and dermal eosinophil infiltration may be observed, without a subepidermal blister.

Direct immunofluorescence (DIF): The typical finding of BP is linear IgG and C3 deposition along the basement membrane zone in normal-appearing perilesional skin. IgA and IgM deposition is rare. DIF sensitivity is about 90~95%, and on NaCl-split skin DIF, fluorescence on the epidermal side is characteristic (vs epidermolysis bullosa acquisita: dermal side). Specimens need to be stored in Michel's solution or as frozen sections.

ELISA: A positive anti-BP180 NC16A ELISA is central to the diagnosis. Titers may be lower in patients receiving systemic steroids. Combining anti-BP230 ELISA improves diagnostic sensitivity. In DPP-4 inhibitor-induced BP, antibodies to non-NC16A BP180 epitopes predominate, so the standard NC16A ELISA may be negative; in this case, full-length BP180 ELISA or immunoblot is needed.

10. Treatment

BP treatment aims to suppress blistering, relieve pruritus, maintain immunosuppression, and minimize adverse effects. Because the risk of adverse effects from high-dose systemic steroids is high in elderly patients, potent topical steroids are strongly recommended as first-line treatment even in moderate~severe disease.

Potent topical corticosteroids: Whole-body application of clobetasol propionate 0.05% cream 30~40 g/day is the standard first-line treatment. In the 2002 trial by Joly et al., topical steroids achieved higher survival than systemic steroids in severe BP. After induction of remission, gradual tapering (15~20 g/day after 2 months, aiming for complete discontinuation after 4 months). With extensive application there is a risk of adrenal suppression, so periodic assessment is needed.

Systemic corticosteroids: Prednisolone 0.5 mg/kg/day is used in moderate~severe disease in combination with topical steroids or alone. In elderly patients, because of the risks of osteoporosis, diabetes, and infection, the goal is low-dose, short-term use followed by tapering where possible.

Doxycycline ± niacinamide: Effective in controlling BP through immunomodulatory and anti-inflammatory effects, and used as first-line treatment or for steroid sparing in elderly patients in whom systemic steroid adverse effects are a concern. The combination of doxycycline 200 mg/day + niacinamide 2.25 g/day has been validated in several studies.

Steroid-sparing immunosuppressants: Methotrexate (5~12.5 mg/week), azathioprine (1~3 mg/kg/day), and mycophenolate mofetil (2 g/day) are used to prevent relapse and taper steroids. In elderly patients, renal function and blood counts are monitored regularly.

Omalizumab: An anti-IgE monoclonal antibody targeting the IgE-mediated mechanism of BP; efficacy in refractory BP has been reported in small studies. Dupilumab: A biologic blocking the IL-4/13 receptor; efficacy has been confirmed in small open-label studies and case reports in Th2-skewed BP, and it is tried in refractory or elderly high-risk BP.

11. Prognosis

The prognosis of bullous pemphigoid is better than that of pemphigus, but because it occurs mainly in elderly patients, mortality is high due to comorbidities and complications of immunosuppressive treatment. Mortality within 1 year after diagnosis is reported as about 20~40% depending on the study, mainly due to coexisting cardiovascular disease of old age, pneumonia, and sepsis. Treatment-related infections and the frailty of old age, rather than the disease itself, are the main causes of death.

Complete remission is achieved in about 40~60% within 1~2 years after starting treatment. Relapse is common, occurring in 30~40% after treatment discontinuation. Predictors of relapse include high anti-BP180 titers, extensive skin involvement, and neurological comorbidities. The prognosis is particularly poor in BP patients with neurological diseases (Alzheimer disease, Parkinson disease), due to the poor prognosis of the neurological disease itself and the cumulative adverse effects of immunosuppressive treatment. In terms of quality of life, control of pruritus is a key element in improving prognosis.

12. Prevention

Primary prevention of bullous pemphigoid is not possible, but prevention of relapse and complications is important. In patients with drug-induced BP (DPP-4 inhibitors, dupilumab, etc.), discontinuing or replacing the causative drug is the first prevention strategy. Regular follow-up (anti-BP180 ELISA, clinical assessment) is essential to detect relapse early after maintenance treatment is stopped. During use of potent topical steroids, the application area and dose are minimized along with regular assessment to prevent skin atrophy, skin infection, and adrenal suppression. In elderly patients, fall prevention, nutritional management, and vaccinations (pneumococcal, influenza, herpes zoster) are important for preventing associated complications. Prevention of osteoporosis (bisphosphonates, calcium, vitamin D) is recommended during steroid use.

13. References

  1. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. DOI: 10.1056/NEJMoa011592. PMID: 11821508.
  2. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-332. DOI: 10.1016/S0140-6736(12)61160-5. PMID: 23237497.
  3. Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid. J Am Acad Dermatol. 2012;66(3):479-485. DOI: 10.1016/j.jaad.2011.06.032. PMID: 21641083.
  4. Kridin K, Ludwig RJ. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Front Med. 2018;5:220. DOI: 10.3389/fmed.2018.00220. PMID: 30131958.
  5. Izumi K, Nishie W, Mai Y, et al. Autoantibody Profile Differentiates Drug-induced Bullous Pemphigoid from Its Spontaneous Counterpart. J Invest Dermatol. 2016;136(11):2201-2210. DOI: 10.1016/j.jid.2016.06.622. PMID: 27424293.
  6. Stinco G, Codutti R, Frattasio A, Patrone P. A retrospective study on the association between bullous pemphigoid and neurological diseases. Acta Derm Venereol. 2005;85(2):136-139. DOI: 10.1080/00015550410025247. PMID: 15823910.
  7. van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous disorders. J Dtsch Dermatol Ges. 2018;16(9):1077-1091. DOI: 10.1111/ddg.13637. PMID: 30144401.
  8. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867-877. DOI: 10.1111/bjd.13717. PMID: 25403366.
  9. Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as prurigo pigmentosa. JAMA Dermatol. 2013;149(8):950-953. DOI: 10.1001/jamadermatol.2013.4152. PMID: 23784014.
  10. Zhao CY, Murrell DF. Bullous pemphigoid treatment. Expert Opin Pharmacother. 2020;21(11):1367-1379. DOI: 10.1080/14656566.2020.1758641. PMID: 32367764.